Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma
Conditions: Glioblastoma, IDH-Wildtype

Interventions: Procedure: Archive Sample Retrieval; Procedure: Biospecimen Collection; Procedure: Chest Radiography; Procedure: Echocardiography Test; Drug: EGFR/EGFRvIII Inhibitor WSD0922-FU; Procedure: Magnetic Resonance Imaging; Drug: Temozolomide

Sponsors: Mayo Clinic

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 17, 2026Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments